Clinical trial
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic…
NCT00388336 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00388336 |
|---|---|
| Title | PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy |
| Official title | A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 60,000 Units Every Two Weeks in Anemic Cancer Patients Not Receiving Chemotherapy Or Radiation Therapy |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Clinical Affairs, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Neoplasms |
| Intervention type | Drug |
| Interventions | Epoetin Alfa |
| Enrollment | 57 |
| Start date | Feb 1, 2004 |
| Completion | Mar 1, 2005 |
| First posted | Oct 16, 2006 |
| Last update posted | May 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: